Search
 
NEWS
 

Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma - Marketscreener.com

 
 
MINNEAPOLIS, Dec. 14, 2022 -- Panbela Therapeutics, Inc. , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today... | December 14, 2022 - READ MORE
By Marketscreener.com
Wed, 14 Dec 2022 14:01:25 GMT
 
PREVIOUS NEXT
Mistakes to avoid when figuring out how soon to take your CPP. Plus, a former lawyer warns about too much isolation in retirement - The Globe and Mail
Future Loss of Income Awards: Deductibility of Private Pension and CPP Benefits - Lexology
When to Apply for Your CPP - MountainviewToday.ca - Mountain View TODAY
CPP Dreamers may be in jeopardy after DACA court decision - The Poly Post
Two mistakes people make when calculating when to start CPP based on life expectancy - The Globe and Mail
Inflation Is Boosting TFSA, OAS and CPP Payments, but It’s Not Enough to Create Wealth - Yahoo Canada Finance
Insights on the CPP Packaging Films Global Market to 2027 - U.S. Market is Estimated at $1.4 Billion - ResearchAndMarkets.com - Business Wire
CPP Investments Increases Net Assets to $529 Billion at End of Second Quarter 2023 | Chief Investment Officer - Chief Investment Officer
Tagged: #Panbela #Receives #Positive #EMA #Opinion #Orphan #Designation #Ivospemin #Combination #Gemcitabine #Patients #Metastatic #Pancreatic #Ductal #Adenocarcinoma
ADD COMMENT
Topic
Name
4+2 =